Home » Topics » Regulatory » EMA

EMA
RSS

Starpharma reaches agreement with EMA on phase III program for VivaGel

Nov. 21, 2011

AstraZeneca receives positive CHMP opinion for vandetanib

Nov. 21, 2011

EMA accepts Nuedexta MAA for filing

Nov. 18, 2011

AMT's gene therapy for hemophilia B given orphan drug status in Europe

Nov. 16, 2011

FDA and EMA accept Astellas' submissions for mirabegron

Nov. 15, 2011

Merck Sharp & Dohme withdraws MAA for fixed-dose combination of sitagliptin and pioglitazone

Nov. 15, 2011

EC withdraws marketing authorization for Ablavar

Nov. 14, 2011

Novartis presents key developments of third quarter 2011

Nov. 11, 2011

Discovery Labs' lucinactant gains European orphan drug status

Nov. 4, 2011

European orphan drug status for Celldex Therapeutics' rindopepimut

Nov. 2, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 6, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 5, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.